Company intelligence / Profile preview

TCT Oncology

Turkey

Ownership: Private
Development stage: Preclinical

Overview

TCT appears to be a healthcare technology company that partners with biotechnology companies to bring innovative therapies to Turkey. They collaborate with companies like GI Innovation and AbClon to introduce treatments for cancer and other diseases.

Therapeutic areas: OncologyImmunology
Modalities: Cell therapiesMonoclonal antibodiesBispecific fusion proteinsCAR-T therapies
Industry: Consulting

Drug pipeline

1 asset

64/67Cu-SAR-trastuzumab

Pre-clinical

Indications: HER2-positive breast cancer

Partnerships

GI InnovationAbClon

Beyond the preview

Go deeper on TCT Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TCT Oncology.

Explore the full profile